Iron supplementation in preterm infants treated by recombinant human erythropoietin;Supplementation en fer chez les enfants prematures traites par erythropoietine

Archives de Pediatrie

Volumn 6, Issue 6, 1999, Pages 657-664

  Picaud, J C ^a   Putet, G ^b   Salle, B L ^a   Claris, O ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL DEBROUSSE   (France)

Author keywords

Anemia, neonatal; Erythroprotein; Infant, premature; Iron

Indexed keywords

EDETATE FERRIC SODIUM; FER UCB; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS ASCORBATE; FERROUS FUMARATE; INOFER; IRON; IRON DEXTRAN; IRON SACCHARATE; IRON SORBITEX; LOSFERON; MALTOFER; RECOMBINANT ERYTHROPOIETIN; TARDYFERON; TOT HEMA; UNCLASSIFIED DRUG; VIT 500; ANTIANEMIC AGENT; FERRIC ION; FERRIC OXIDE, SACCHARATED; IRON POLYMALTOSE;

DIET SUPPLEMENTATION; DRUG FORMULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON ABSORPTION; IRON THERAPY; KIDNEY FAILURE; NEWBORN ANEMIA; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; PREMATURITY; REVIEW; SIDE EFFECT; ADULT; CHRONIC KIDNEY FAILURE; NEWBORN;

ADULT; DIETARY SUPPLEMENTS; ERYTHROPOIETIN, RECOMBINANT; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC;

EID: 0033143809     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80299-1     Document Type: Article

References (58)

1. Erslev AJ. Humoral regulation of red cell production. Blood 1953; 8 : 349-57.
2. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82 : 7580-4.
3. Stockman JA III, Graeber JE, Clark DA, Mc Clellan K, Garcia JF, KaveREW. Anemia of prematurity: Determinants of the erythropoietin response. J Pediatr 1984; 105 : 786-92.
4. Maier RF, Obladen M, Scigalla T, Linderkamp O, Duc G, Hieronimi G, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very low-birth-weight infants. N Engl J Med 1994; 330 : 1173-8.
5. Carnielli V, Montini G, Da Riol R, Dall' Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr 1992; 121 : 98-102.
6. Meyer MP, Meyer JH, Commerford A, Sive AA, Moller G, Jacobs P, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of double-blind, placebo-controlled study. Pediatrics 1994; 93 : 918-23.
7. Messer J, Haddad J, Donato L, Astruc D, Matis J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 1993; 92 : 519-23.
8. es Journées. Paris : Karger; 1998. p. 263-75.
9. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989; 111 : 992-1000.
10. Canadian erythropoitein study group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-8.
11. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989;4 : 979-87.
12. Edmunds ME, Walls J, Tucker B, Baker LR, Tomson CR, Ward M, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4 : 1065-9.
13. Obladen M, Maier R, Segerer R, Grauel EL, Holland BM, Stewart G, et al. Efficacy and safety of recombinant human erythropoietin to prevent the anemia of prematurity. Contrib Nephrol 1991; 88 : 314-26.
14. Mentzer WC, Shannon KM, Abels RI, Freeman P, Newton N, Thompson D, Phibbs R. A randomized, placebo-controlled clinical trial of recombinant human erythropoietin in the anemia of prematurity. Contrib Nephrol 1991; 88 : 306-12.
15. Movilli E, Cancarini GC, Mombelloni S. The role of hematocrit in efficiency of dialysis. Blood Purif 1990; 8 : 183-9.
16. Granolleras C, Leskopf W, Shaldon S. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: A randomised double-blind crossover study. Clin Nephrol 1991; 36 : 294-8.
17. Veys N, Vanholder R, Lamiere N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance haemodialysis patients: A comparison of two brands of erythropoietin. Am J Nephrol 1992; 12 : 68-72.
18. MacDougall IC, Coles GA, Williams JD. Inhibition of a response to erythropoietin in the presence of infection of malignancy. Erythropoiesis 1992; 3 : 29-30.
19. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328 : 171-5.
20. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80 : 1639-47.
21. Ballal SH, Domoto DT, Polack DS, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17 : 29-33.
22. Carozzi S, Nasini MG, Schelotto C, Santoni O. 1,25 (OH) 2D3 and human recombinant erythropoietin: Effects on erythropoiesis in CAPD. Nephrol Dial Transplant 1993; 8 : 956.
23. Pronai W, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephrol Dial Transplant 1993; 8 : 962.
24. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989; 299 : 157-8.
25. Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 (Suppl 2) : 85-91.
26. Rosenberg ME. Role of transferrin measurement in monitoring iron status during recombinant human erythropoietin therapy. Dial Transplant 1992; 21 : 81-90.
27. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, et al. Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 1992; 304 : 225-6.
28. Rusia U, Flowers C, Madan N, Agarwal N, Skood SK, Sikka M. Serum transferrin receptor levels in the evaluation of iron defiency in the neonate. Acta Paediatr Japonica 1995; 38 : 455-9.
29. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964; 37 : 62-70.
30. Cavill I. Diagnostic methods. Clinics in Haematology 1982; 11 : 259-73.
31. Cavill I, Macdougall IC. Erythropoiesis and iron supply in patients treated with erythropoietin. Erythropoiesis 1992; 3 : 50-5.
32. Lundström U, Siimes MA, Dallman PR. At what age does iron supplementation become necessary in low-birth-weight infants? J Pediatr 1977; 91 : 878-83.
33. Shannon KM, Keith JF, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low-birth-weight preterm infants. Pediatrics 1995; 95 : 1-8.
34. Halperin DS, Wacker P, Lacourt G, Felix M, Babel JF, Aapro M, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J Pediatr 1990; 116:779-86.
35. Saarinen UM, Siimes MA, Dallman PR. Iron absorption in infants: High bioavailability of breast milk iron as indicated by the extrinsic tag method of iron absorption and by the concentration of serum ferritin. J Pediatr 1977; 91 : 36-9.
36. Dauncey MJ, Davies CG, Shaw JCL, Urman J. The effect of iron supplements and blood transfusion on iron absorption by low birthweight infants fed pasteurized human breast milk. Pediatr Res 1978; 12 : 899-904.
37. Zlotkin SH, Lay DM, Kjarsgaard J, Longley T. Determination of iron absorption using erythrocyte iron incorporation of two stable isotopes of iron (57Fe and 58Fe) in very low-birth-weight premature infants. Pediatr Gastroenterol Nutr 1995 : 21; 190-9.
38. Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996, 129: 258-63.
39. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneim-Forsch Drug Res 1992; 42: 1439-52.
40. Theil EC, Sayers DE, Brown MA. Similarity of the structure of ferritin and iron dextran (imferon) determined by extended X-ray absorpition fine structure analysis. J Biol Chem 1979; 254 : 8132-4.
41. Schneider W. The fate of iron compounds in the gastrointestinal tract. Coordination-chemical facts. Arzneim-Forsch 1987; 37 : 92-5.
42. Jacobs P, Fransman D, Coghlan P. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blodd donors [Published erratum appears in J Clin Apheresis 1994; 9 : 26].
43. J Clin Apheresis 1993; 8(2) : 89-95.
44. Fletcher LM, Roberts FD, Irving MG, Powell LW, Halliday JW. Effects of iron loading on free radical scavenging enzymes and lipid peroxydation in rat liver. Gastroenterology 1989; 97 : 1011-8.
45. Jacobs J. Death due to iron parenterally. South Med J 1969; 37 : 216-9.
46. Friel JK, Andrews WL, Hall MS, Rodway MS, Keith M, Mac Cloy UC, et al. Intravenous iron administration to very low-birth-weight newborns receiving total and partial parenteral nutrition. J Parenter Enterai Nutr 1995; 19 : 114-8.
47. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 1996; 128 : 518-23.
48. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythro-poietin on the transfusion requirements of preterm infants weighing 750 grams or less: A randomized, double-blind, placebo-controlled study. J Pediatr 1997; 131 : 661-5.
49. James JA, Combes M. Iron deficiency in premature infants. Pediatrics 1960; 23 : 368-70.
50. Scott PH, Berger HM, Kenward C Scott P, Wharton BA. Effect of gestational age and intrauterine nutrition on plasma transferrin and iron in the newborn. Arch Dis Child 1975; 50 : 796-800.
51. Farmer K. The disadvantages of routine administration of intramuscular iron to neonates. New Zeal Med 1976; 84 : 286-7.
52. Barry DMJ, Reeve AW. Increased incidence of gram-negative neonatal sepsis with intramuscular iron administration. Pediatrics 1977;60 : 908-12.
53. Lieken SL. The use of intramuscular iron in the prophylaxis of the iron-deficiency anemia of prematurity. J Dis Child 1960; 53 : 739-45.
54. Sitarz AL, Wolf JA, VonHofe FH. Comparison of oral and intramuscular administration of iron for prevention of the late anemia of premature infants. Pediatrics 1960; 23 : 375-84.
55. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243 : 1726-31.
56. Michaud L, Gottrand F, Froger H, Dubar G, Boutoutaou C, Turck D. Utilisation du fer saccharate par voie intraveineuse chez l'enfant en nutrition parentérale prolongée présentant une carence en fer [Abstract]. Nutrition Clinique et Métabolisme 1997; 11 : 314.
57. Lavoie JC, Chessex P. Bound iron admixture prevents the spontaneous generation of peroxides in total parenteral nutrition solutions. Pediatr Gastroenterol Nutr 1997 25 : 307-11.
58. Pitkanen O, Hallman M, Anderson S. Generation of free radicals in lipid emulsion used in parenteral nutrition. Pediatr Res 1991; 29: 56-9.